These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 834952)

  • 1. [Blood uric acid in myeloma].
    Caplain-Dandine F; Kahn MF; de Sèze S
    Rev Rhum Mal Osteoartic; 1977 Jan; 44(1):1-4. PubMed ID: 834952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.
    Iseki K; Ikemiya Y; Inoue T; Iseki C; Kinjo K; Takishita S
    Am J Kidney Dis; 2004 Oct; 44(4):642-50. PubMed ID: 15384015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of hyperuricemia during cytostatic therapy].
    Kolb S; Sailer D; König HJ
    Fortschr Med; 1982 Dec; 100(46):2159-61. PubMed ID: 7152443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
    Pasqualetti P; Colantonio D; Casale R
    Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate.
    See LC; Kuo CF; Chuang FH; Li HY; Chen YM; Chen HW; Yu KH
    J Rheumatol; 2009 Aug; 36(8):1691-8. PubMed ID: 19531754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma.
    Mateo G; Corral M; Almeida J; López-Berges C; Nieto mJ; García-Marcos A; Vázquez L; del Cañizo C; Orfao A; San Miguel JF
    Haematologica; 2003 Sep; 88(9):1013-21. PubMed ID: 12969809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Bence-Jones proteins, hyperviscosity, hypercalcemia, hyperuricemia and dehydration on development of renal changes in plasma cell dyscrasias.
    Lenert P; Drazen F; Tepavcević P; Pejin D; Curić S; Ilić V; Uzurov V; Popowić S; Zupunski A; Djisalov M
    Przegl Lek; 1985; 42(4):384-6. PubMed ID: 4048525
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
    Umeda M; Okuda S; Izumi H; Nagase D; Fujimoto Y; Sugasawa Y; Arai C; Natori K; Katoh M; Kuraishi Y
    Ann Hematol; 2006 Jul; 85(7):469-73. PubMed ID: 16528526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Urate-oxidase: a new therapy of cytotoxic-drug-induced hyperuricemia (author's transl)].
    Vigo P; Ortolani S; Soldati L; Girardello R; Fleischmann L; Polli EE
    Haematologica; 1981 Oct; 66(5):656-66. PubMed ID: 6796473
    [No Abstract]   [Full Text] [Related]  

  • 15. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.
    Orfäo A; García-Sanz R; López-Berges MC; Belén Vidriales M; González M; Caballero MD; San Miguel JF
    Cytometry; 1994 Dec; 17(4):332-9. PubMed ID: 7533074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow changes following chemotherapy for multiple myeloma--a clinicopathological study of biopsy cases.
    Kurihara K; Hill W; Burkhardt R; Kettner G; Hashimoto N
    Nihon Ketsueki Gakkai Zasshi; 1987 Jul; 50(4):876-89. PubMed ID: 3687331
    [No Abstract]   [Full Text] [Related]  

  • 17. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission.
    Galani Z; Viniou N; Kyrtsonis MC; Sachanas S; Antoniou T; Dimopoulou MN; Vassilakopoulos TP; Korkolopoulou P; Nakopoulou L; Patsouris E; Pangalis GA
    Anticancer Res; 2007; 27(1B):571-4. PubMed ID: 17348443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative therapy for primary resistant multiple myeloma.
    Alexanian R; Dimopoulos MA; Delasalle KB; Hester J; Champlin R
    Stem Cells; 1995 Aug; 13 Suppl 2():118-21. PubMed ID: 8520499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.